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Abstract 
Objective: While the physiological responses during acute ascent to terrestrial high-altitude (HA) 
have the potential to alter the pharmacokinetics (PK) that define the absorption and disposition of 
medicinal drugs, there have been no systematic reviews and meta-analyzes performed to date.  
Methods: We conducted a systematic literature search in June 2017 using NCBI PubMed, 
EMBASE, Web of Science and Ovid MEDLINE databases to identify relevant observational 
studies. Studies were deemed eligible based on the following criteria: [1] participants: healthy 
non-acclimatised male or female lowlanders (born and bred at sea-level) and 2] environment: 
exposure to low-altitude (LA, ≤ 600 m) followed by terrestrial high-altitude (HA, ≤ 24 h to ≥ 2,500 
m), the time course specifically selected to avoid interpretive complications associated with 
erythrocytosis. All PK parameters were standardized to be in the same units and the weighted 
standardised mean difference (SMD) calculated via a combination of fixed and random effects 
models with heterogeneity evaluated using χ2 and I2 statistics. 
Results:  Of 20,840 studies reviewed, 6 prospective cohort studies (n = 75) qualified for inclusion 
with participants exposed to a mean altitude of 4,025 (mean) ± 380 (SD) m. We observed increases 
for absorption half-life (SMD: 0.40, 95% CI: 0.01-0.80, P = 0.04], elimination half-life (SMD: 
0.89, 95% CI: 0.30-1.48, P = 0.003) and erythrocyte binding (SMD: 0.52, 95% CI: 0.16-0.88, P = 
0.004) and reduction in clearance (SMD: -0.56, 95% CI: -1.13-0.00, P = 0.05).  
Conclusions: Collectively, these findings reveal impairments in both the oral absorption and 
corresponding clearance of an albeit limited sample of drugs at HA that may potentially require 
closer patient monitoring and dose adjustments in order to maintain therapeutic efficacy and avoid 
incidental toxicity.   
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Introduction 
The complex interplay between environmental and physical stressors encountered during acute 
ascent to terrestrial high-altitude (HA) initiates a cascade of physiological responses that 
collectively serve to defend oxygen (O2) delivery to the most metabolically active organ systems 
(Bailey and others 2017). However, coupling of O2 delivery to demand is imperfect and severe 
arterial hypoxemia can ultimately lead to medical complications ranging from mild symptoms of 
acute mountain sickness (AMS) to the potentially fatal syndromes of high-altitude pulmonary 
(HAPE)/cerebral (HACE) edema (Bailey and others 2009) that necessitate the use of medicinal 
drugs. 
These physiological adjustments have the capacity to alter the pharmacokinetics (PK) that define 
the absorption and disposition of drugs subsequent to alterations in, amongst others, cytochrome 
P (CYP)-450 activity, pH, protein binding, distribution volumes and perfusion (Figure 1 A-B). 
This is clinically relevant given the millions of lowlanders who sojourn to HA for occupational, 
recreational, or religious purposes (Li and others 2009) and increasing number of mountaineers 
who prophylax with a cocktail of drugs in an attempt to accelerate acclimatization and improve 
summit success (Donegani and others 2016; Nieto Estrada and others 2017).  
However, to what extent drug PK change in response to the multiple stressors encountered at 
terrestrial HA (hypoxia, exercise, cold, see Figure 1) remains unclear, complicated in part by 
conflicting findings from a limited number of studies constrained by small sample sizes and limited 
ability to detect treatment effects with participants exposed to different drugs, altitudes and 
exposure times. Thus, for the first time, a systematic review and meta-analysis was conducted to 
summarize the results of relevant studies in an attempt to increase sample size and corresponding 
statistical power. The primary aim was to determine the effects of acute exposure (≤ 24 h) to 
terrestrial HA on drug PK with a secondary aim of determining optimal sample sizes to help guide 
the design of future trials.  
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Methods  
Database and search strategy  
A systematic review of the published literature was conducted (Figure 2) in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement as a 
guide (Knobloch and others 2011). Specific care was taken to fulfil key requirements to ensure the 
validity of our meta-analysis, namely, [1] well-defined objectives, including precise definitions of 
clinical variables and outcome, [2] an appropriate and well-documented study identification and 
selection strategy, [3] evaluation of bias in the identification and selection of studies, [4] 
description and evaluation of heterogeneity, [5] justification of data analytic techniques and [6] 
use of sensitivity analysis (Walker and others 2008). Two independent investigators interrogated 
NCBI PubMed, EMBASE, Web of Science and Ovid MEDLINE databases before June 27th (2017) 
using the following key words and Boolean connectors: (pharmacokinetics OR pharmacodynamics 
OR drugs OR medicines) AND (altitude OR high-altitude). 
 
Selection and quality assessment  
Inclusion criteria: Studies were deemed eligible for meta-analysis based on the following criteria: 
1] participants: healthy non-acclimatised male or female lowlanders (born and bred at sea-level) 
and 2] environment: exposure to low-altitude (LA, ≤ 600 m) followed by terrestrial high-altitude 
(HA, ≤ 24 h to ≥ 2,500 m).  
Exclusion criteria: We excluded studies that were 1] performed on animals, 2] duplicates 
(originating from the same participants by the same investigators but published in different 
journals), 3] letters to editors, reviews, commentaries, case reports, unpublished articles and 
articles providing insufficient information relating to PK parameters, 4] simulated normobaric 
hypoxic (laboratory-based) studies given the acknowledged physiological differences compared 
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to hypobaric hypoxia (Millet and others 2012) and 5] those incorporating chronic (> 24 h) 
exposures to avoid interpretive (PK) complications associated with erythrocytosis.  
Quality: Study quality could not be formerly assessed given that none of the studies were 
randomised, blinded or provided sample size calculations. Final decision about inclusion or 
exclusion was achieved through mutual agreement.  
 
Data extraction  
The two investigators extracted data using structured data collection tables. All data entries were 
double-checked manually and all discrepancies resolved through discussion. The following 
information was extracted from selected studies: authors, publication year, experimental design, 
drug examined, sample size, altitude and PK parameters. The PK parameters were standardised to 
be in the same units and included: absorption rate constant (kA), volume of distribution as a 
function of bioavailability (Vd/F), mean residence time (MRT), absorption (t½A) and elimination 
(t½) half-lives, clearance as a function of bioavailability (CL/F), elimination rate constant (K), 
time to peak plasma concentration (TMAX) and erythrocyte binding (CE).  
 
Statistical analysis  
Statistical analyses were conducted using the Cochrane Review Manager software (RevMan 
Version 5.3.5 for Windows, Cochrane Collaboration, Oxford, UK, http://www.cc-
ims.net/RevMan) to pool data for each of the PK parameters and associated variables. Continuous 
outcomes were presented as a standardized mean difference (SMD, Hedges g) along with 95% 
conﬁdence intervals (CI). Effect sizes of <0.2, <0.5, <0.8 and >0.8 were considered trivial, small, 
moderate and large, respectively (Cohen 1992). Heterogeneity was evaluated using the Cochran 
χ2-based Q and Higgins I2 statistics that assess the appropriateness of pooling individual study 
results (Higgins and others 2003). Random-effects models (DerSimonian and Laird 1986) were 
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applied if heterogeneity was evident (χ2 P < 0.10/I2 >50%) otherwise fixed-effects models (Mantel 
and Haenszel 1959) were employed. Publication bias was assessed using a Funnel Plot in 
combination with Egger et al.’s test (Egger and others 1997). Power and sample size calculations 
were performed using G*Power (version 3.1.9.2). Significance was established at P < 0.05 for all 
two-tailed tests and data presented as mean ± SD unless otherwise stated. 
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Results  
Study identification and characteristics  
Applying the search terms, a total of 20,840 publications were identified, out of which ten were 
considered relevant after initial screening by title and abstract (Figure 2). After applying the 
inclusion and exclusion criteria, six full-text articles employing separate drugs were selected for 
meta-analysis (Table 1). The general properties of the six drugs are summarized in Table 2. These 
articles constituted non-randomized single-arm studies comprising a total of 75 healthy males of 
either Chinese or Chilean descent. Participants were 21 ± 3 years old and exposed to both LA (267 
± 301 m) and HA (4,025 ± 380 m) for 14.2 ± 1.7 h. There was no consistent evidence of systematic 
publication bias (P > 0.05). 
 
Outcomes 
The drugs appeared to be well tolerated since there were no serious adverse events reported. Figure 
3 provides a summary of the mean changes (SMD) observed in each of the PK parameters 
documented at HA based on the individual studies (Supplementary Figures, S1a-S1j). We 
observed significant increases for t½A (SMD: 0.40, P = 0.04) and t½ (SMD: 0.89, P = 0.003) while 
the hybrid parameter CL/F showed a corresponding reduction (SMD: -0.56, P = 0.05). These were 
considered of potential physiological significance given the SMD “cut-off” of ≥ 0.50 standardized 
units as illustrated (Figure 3). In contrast, no changes (P > 0.05) were observed in the remaining 
parameters, notably kA, TMAX, Vd/F or K (latter SMD: -0.53). Similarly MRT while not significant, 
showed a marked tendency to be increased (SMD: 0.56, P = 0.09).  Finally and as expected, 
significant increases in Hct (SMD: 1.02, P = 0.01) and CE (SMD: 0.52, P = 0.004) were observed. 
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Statistical power and sample size  
Post-hoc analyses revealed that studies were generally underpowered with no singular 
pharmacokinetic parameter achieving the (minimal) requisite power of 0.8 (Figure 4). Prospective 
calculations indicated that sample sizes needed to be in the order of ~2 to over 1,500 fold larger in 
order to be adequately powered to detect a treatment effect.   
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Discussion 
This systematic review and meta-analysis has revealed important changes in PK parameters that 
define the absorption and disposition of an albeit limited selection of medicinal drugs displaying 
diverse physico-chemical and PK properties that may be indicative of a broader impact of the HA 
environment upon the body’s handling of pharmaceuticals. First, by pooling relevant studies and 
improving statistical power, our analysis extends original works described in a published review 
(Hui and others 2016) highlighting impairments in both the oral absorption and corresponding 
clearance of drugs that from a clinical perspective, encourage the need for closer patient 
monitoring and dose adjustments in order to maintain therapeutic efficacy and avoid incidental 
toxicity. Second, prospective calculations have helped inform the design of future trials 
highlighting the need for considerably larger sample sizes to more rigorously address PK changes 
and ultimately define safer, more effective pharmacological interventions at HA.  
The overall outcomes of our analysis highlighted a significant prolongation in t1/2A at HA. This 
change in rate is not necessarily underpinned by any change in the extent of absorption 
[bioavailability (F)], a parameter not reported in any of the primary studies forming this meta-
analysis.  Our analysis would suggest that the data for sulfamethoxazole, meperidine and lithium 
made the greatest contribution to the overall absorption outcomes of our study.  These drugs 
possess different biopharmaceutical characteristics in respect to the Biopharmaceutics 
Classification System (BCS) for orally administered drugs (Kasim and others 2004). 
Sulfamethoxazole is a Class IV drug (low permeability and low solubility) whereas meperidine 
and lithium (WHO 2005) are Class I drugs (high permeability and high solubility). The other drugs 
in the analysis being: acetazolamide (Class IV), furosemide (Class IV) and prednisolone (Class I).   
However, there is little that can be concluded from such biopharmaceutical characteristics in terms 
of a unifying mechanism to support a slower absorption rate at HA and the BCS system itself does 
not provide a definitive measure of in-vivo absorption outcomes.   
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Acute exposure to HA is often associated with gastrointestinal complaints attributed to delayed 
gastric emptying, although more severe hypoxemia associated with higher elevations (>5000 m) 
is typically required before nutrient malabsorption becomes apparent (Bailey and others 2004; 
Bailey and others 2001; Bailey and others 2000). The absorption of Class IV drugs such as 
sulfamethoxazole are generally not affected by gastric emptying but by other complex and variable 
issues acting on the drug formulation within the gastro-intestinal tract.  Further, the meperidine 
data in this analysis was represented as a drug delivered via the intra-muscular route. Changes in 
hemodynamics at the absorption site (intestinal or intra-muscular) could be responsible for slowed 
drug absorption as indicated by one study that reported a reduction in superior mesenteric blood 
flow both before and following a standard meal in response to acute exposure (2h) to hypobaric 
hypoxia equivalent to a simulated altitude of 4,800 m (Loshbaugh and others 2006). Similarly, 
subtle effects of a hypobaric hypoxic environment upon local capillary pressures and epithelial-
luminal biochemistry including membrane carriers, metabolism and local intestinal secretions that 
influence pH could be highly relevant to the drug absorption process. 
We observed a consistent increase in CE that has traditionally been attributed to an increase in Hct 
and/or total protein including albumin assuming CE includes all sources of binding in blood (Hui 
and others 2016). In the current study, we specifically chose to focus our attention on acute HA 
exposure (< 24 h) and thus confident that the increase in CE was unrelated to any increase in 
erythrocyte mass given the 2-3 day time-lag between erythropoiesis and de novo appearance of 
reticulocytes in the circulation. Thus, the increased Hct observed likely reflects an apparent 
hemoconcentration subsequent to hyperventilation/diuresis-induced plasma volume contraction, 
notwithstanding potential increases in capillary hydrostatic and interstitial osmotic pressures that 
collectively drive fluid from the intravascular to the extravascular space (Fall and others 2011).  
The analysis revealed a consistent and significant trend for the CL/F parameter to be reduced at 
HA. The decrease in CL/F could reflect decreases in CL and/or increases in F. However increases 
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in F would not be consistent with a trend for a reduced rate of absorption and moreover the Vd/F 
parameter remained essentially unchanged indicating neither Vd or F to have changed 
significantly, or both parameters to have changed in a simultaneous and directly proportional 
manner, i.e. if F were to have increased then Vd would also need to have increased in direct 
proportion. In this context while acute HA exposure can be associated with fluid extravasation any 
such conductive fluid transfer would not in its own right change the effective estimate for Vd, 
when this estimate is based upon total drug plasma concentrations, which is indeed the case in the 
primary studies underpinning the analysis of this systematic review.  As such we interpret the 
reduced CL/F to reflect a decrease in CL per se, entirely consistent with the prolonged t½ and 
indeed the trend for MRT to be prolonged in the studies, although it is important to note that the 
method of calculation of the MRT parameter was not explicitly defined in most of the primary 
works. The apparent discrepancy between t½ and K (the latter not significant), although trending 
towards an (expected) inverse relationship, is a likely consequence of the marked heterogeneity of 
the SMDs associated with each of the selected studies. 
Previous observed or presumed decreases in drug CL at HA have more often than not been 
interpreted in the context of altered capacity for enzymatic metabolism, particularly diminished 
monooxygenase activity of CYP-450 for which O2 is a substrate (Fradette and Du Souich 2004). 
However, a drug’s CL (i.e. one based on measurement of total protein-bound and free drug levels) 
may also be impacted by changes in drug plasma protein binding. This is particularly the case for 
those drugs displaying medium to low extraction efficiencies across an organ(s) of elimination 
where a change in the fraction of unbound drug in plasma (Fu) may deliver concordant change in 
a drug’s total (bound and unbound) plasma CL. In the context of the current molecules and with 
respect to metabolism-mediated elimination, any potential HA-induced changes in Fu could 
possibly impact upon the CL of prednisolone and sulfamethoxazole, as examples of medium to 
low extraction drugs. However, the CL/F of prednisolone, a drug recognized to display 
12   R2 
 
concentration-dependent changes in Fu (Al-Habet and Rogers 1980; Frey and others 1986), did 
not change at HA in the primary study (Arancibia and others 2005). A number of drugs in the 
present analysis have limited or no metabolic elimination but rather substantial renal excretion 
(acetazolamide, furosemide and lithium) but nevertheless displayed in the primary studies 
significantly reduced CL/F with HA exposure. Collectively, this raises the potential role of altered 
hemodynamics in HA-induced changes in CL either through direct or indirect mechanisms. The 
extent by which HA alters renal hemodynamics remains equivocal (Goldfarb-Rumyantzev and 
Alper 2014) despite some evidence for a reduction in glomerular filtration rate at comparable 
elevations (Pichler and others 2008). Collectively, our findings are broadly consistent with those 
reported in the animal/in-vitro literature with the reduction in drug clearance classically attributed 
to hypoxia though the additional impact of other environmental stressors typically encountered at 
HA such as exercise and cold (highlighted in Figure 1A) warrant investigation (Bailey 2017). 
However, these findings contrast with those reported during more controlled laboratory-based 
exposures to normobaric hypoxia. In one of the most rigorous trials conducted to date, 2 h passive 
exposure to a simulated altitude of 4,500 m failed to alter hepatic blood flow and corresponding 
metabolism of theophylline (low hepatic extraction ratio metabolized mainly by CYP1A2) and 
verapamil (high hepatic extraction ratio metabolized mainly by CYP3A4), arguing against the need 
for dose adjustment (Streit and others 2005). Differences between normobaric versus hypobaric 
hypoxia (Millet and others 2012) notwithstanding the contributory impact of additional stimuli 
such as exercise, cold and psychological stress exclusive to terrestrial ascent (Bailey 2017; Peng 
and Cheung 2009; Peng and Cheung 2011) may contribute at least in part to these conflicting 
findings and clearly highlight the need for further research.   
 
 
 
13   R2 
 
Limitations 
It is important to recognize the limitations associated with the current meta-analysis. Our findings 
are restricted to participants of either Chilean or Chinese descent and thus the interpretive 
implications for other ethnic groups remains unclear, especially given established differences in 
the catalytic activities of CYP-450 isoforms (Yang and others 2012). Furthermore and subject to 
inclusion/exclusion criteria, our analysis was confined to a limited selection of compounds that 
exhibit diverse clearance pathways and thus it is unlikely that changes in active tubular ion 
exchange, oxidative metabolism, phase II pathways such as N-acetylation, sulfation, and 
glucuronidation or active tubular efflux can collectively be ascribed to a single “common 
mechanism” induced by HA. The situation is clearly more complex, further complicated by 
exposure to multiple stressors whose independent and combined impact on drug PK remain largely 
unknown. Equally, it may be considered pharmacologically unfounded to pool study data from 
such physiochemically diverse compounds, the fundamental basis of a meta-analysis, though we 
have adhered to stringent guidelines (Knobloch and others 2011; Walker and others 2008) 
including a description and evaluation of heterogeneity, to optimize the validity of our findings.  
 
Conclusion 
This analysis reveals impairments in both the oral absorption and corresponding clearance of an 
albeit limited sample of drugs that exhibit diverse clearance pathways that may potentially require 
modifications in dosage regimens to maintain efficacy or prevent toxicity especially for those with 
a narrow therapeutic index. Given that studies have traditionally been underpowered, characterized 
by a high degree of variability and relatively small effect sizes, larger scale randomized controlled  
trials in humans are encouraged to better define safer and more effective pharmacological 
interventions at HA including the experimental (laboratory-based) isolation of the independent and 
combined influences of the composite PK-modulating stressors (hypoxia, exercise, cold). Given 
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the prevalence of drug use at HA (Donegani and others 2016), it would seem reasonable to extend 
PK research to other commonly used drugs for prevention and treatment of HA illness including 
AMS, HAPE and HACE as recently highlighted (Nieto Estrada and others 2017), namely, steroids 
(budesonide, dexamethasone), bronchodilators (salmeterol, theophylline or aminophylline, 
montelukast), phosphodiesterase 5-inhibitors (tadalafil, sildenafil), calcium channel modulators 
(nifedipine, flunarizine), non-steroidal anti-inflammatories and other analgesics (aspirin, 
carbasalate, ibuprofen) . Furthermore, it would be equally important to include those drugs 
commonly prescribed to treat pre-existing cardiovascular, cerebrovascular, metabolic, endocrine 
and pulmonary diseases within a tourist population (antiplatelets, statins, β-blockers, nitrates, 
angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists). 
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